Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: Results of two randomized, double-blind, placebo-controlled studies

International Journal of Dermatology

Volumn 49, Issue 7, 2010, Pages 818-828

  Langley, Richard G ^a   Papp, Kim ^b   Bissonnette, Robert ^c   Toth, Darryl ^d   Matheson, Robert ^e   Hultquist, Micki ^f   White, Barbara ^f  

^a DALHOUSIE UNIVERSITY   (Canada)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c INNOVADERM RESEARCH   (Canada)

^d Tecumseh Road East ^*  (Canada)

^e OREGON MEDICAL RESEARCH CENTER   (United States)

^f MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIPLIZUMAB; CD2 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTERIOSCLEROSIS; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; CHILL; CHOLECYSTITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS SPASM; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROENTERITIS; HEADACHE; HUMAN; HYPERVENTILATION; IMMUNOGENICITY; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OSTEOARTHRITIS; PHASE 2 CLINICAL TRIAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; VASODILATATION; COMPARATIVE STUDY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PLACEBOS; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954164123     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04512.x     Document Type: Article

References (41)

1. Gottlieb SL, Gilleaudeau P, Johnson R. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995, 1:442-447.
2. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996, 98:1878-1887.
3. Inaoki M, Sato S, Shirasaki F. The frequency of type 2 CD8 + T cells is increased in peripheral blood from patients with psoriasis vulgaris. J Clin Immunol 2003, 23:269-278.
4. Austin LM, Ozawa M, Kikuchi T. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999, 113:752-759.
5. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and " type 1" inflammatory gene expression. Trends Immunol 2004, 25:295-305.
6. Gniadecki R, Calverley MJ. Emerging drugs in psoriasis. Expert Opin Emerg Drugs 2002, 7:69-90.
7. Vena GA, Cassano N. Emerging drugs for psoriasis. Expert Opin Emerg Drugs 2006, 11:567-596.
8. Sterry W, Barker J, Boehncke WH. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004, 151:3-17.
9. Leonardi C, Menter A, Hamilton T. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008, 158:1107-1116.
10. Goffe B, Papp K, Gratton D, Krueger GG. Long-term safety of alefacept in patients who have received up to nine courses of therapy [Abstract]. J Am Acad Dermatol 2005, 52. P190-Abstract P
11. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006, 298:7-15.
12. Rott S, Mrowietz U. Recent developments in the use of biologics in psoriasis and autoimmune disorders. the role of autoantibodies. BMJ 2005, 330:716-720.
13. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000, 42:796-802.
14. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001, 345:248-255.
15. Krueger GG, Papp KA, Stough DB. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002, 47:821-833.
16. Menter A, Cather JC, Baker D. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006, 54:61-63.
17. Lebwohl M, Christophers E, Langley R. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003, 139:719-727.
18. Leonardi CL, Powers JL, Matheson RT. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349:2014-2022.
19. Papp KA, Tyring S, Lahfa M. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005, 152:1304-1312.
20. Chaudhari U, Romano P, Mulcahy LD. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001, 357:1842-1847.
21. Gottlieb AB, Evans R, Li S. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004, 51:534-542.
22. Reich K, Nestle FO, Papp K. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366:1367-1374.
23. Menter A, Feldman SR, Weinstein GD. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007, 56:31.
24. Sladden MJ, Mortimer NJ, Hutchinson PE. Extensive plaque psoriasis successfully treated with adalimumab (humira). Br J Dermatol 2005, 152:1091-1092.
25. Gordon KB, Langley RG, Leonardi C. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006, 55:598-606.
26. Wozel G, Sticherling M. Systemic psoriasis therapy - the next step: Adalimumab. Hautarzt 2007, 58:515-524.
27. Papp K, Bissonnette R, Krueger JG. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001, 45:665-674.
28. Jullien D, Prinz JC, Langley RG. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004, 208:297-306.
29. Dubertret L, Sterry W, Bos JD. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006, 155:170-181.
30. Genentech announces voluntary withdrawal of Raptiva from the U.S. market [press release]. http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=12047, Available at: Accessed December 3, 2009
31. Krueger GG, Langley RG, Leonardi C. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580-592.
32. Branco L, Barren P, Mao SY. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999, 68:1588-1596.
33. de la Parra B, van den Branden K, Smyej I, Bazin H. Inhibition of T cell activation by LO CD2 a, a rat monoclonal antibody against the human CD2 glycoprotein. Belg J Zool 1991, 121(suppl 1):13.
34. Moingeon PE, Lucich JL, Stebbins CC. Complemen-tary roles for CD2 and LFA-1 adhesion pathways during T cell activation. Eur J Immunol 1991, 21:605-610.
35. Bierer BE, Sleckman BP, Ratnofsky SE, Burakoff SJ. The biologic roles of CD2, CD4, and CD8 in T-cell activation. Annu Rev Immunol 1989, 7:579-599.
36. Schad V, Greenstein JL, Giovino-Barry V. An anti-CD2 monoclonal antibody that elicits alloantigen-specific hyporesponsiveness. Transplant Proc 1996, 28:2051-2053.
37. Langley R, Roenigk H, McCall C. Phase I results of intravenous MEDI-507, an anti-T-cell monoclonal antibody, for the treatment of psoriasis [Abstract]. J Invest Dermatol 2001, 117:817.
38. Matheson R, Beutner K, McCall C, Dingivan C. Subcutaneous injections of MEDI-507, an anti-T-cell monoclonal antibody, for the treatment of psoriasis: phase I results [Abstract]. J Invest Dermatol 2001, 117:817.
39. Martin A, Gutierrez E, Muglia J. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J Am Acad Dermatol 2001, 45:871-881.
40. Rongioletti F, Fiorucci C, Parodi A. Psoriasis induced or aggravated by drugs. J Rheumatol Suppl 2009, 83:59-61.
41. White B, Harris B. Long-term safety profile of siplizumab, a humanized anti-CD2 monoclonal antibody, in subjects with chronic plaque psoriasis. Internet J Dermatol 2009, 7(2). http://www.ispub.com/journal/the_internet_journal_of_dermatology.html, Available at: